Table II.
Histopathological findings from the 10 patients.
| Marker | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| CD34 | + | + | + | + | + | + | + | − | + | + |
| Bcl-2 | − | + | − | + | − | + | − | + | − | + |
| CD99 | + | + | + | − | + | − | − | + | + | − |
| Vimentin | + | − | − | + | + | + | + | − | + | + |
| Smooth muscle actin | − | − | − | + | − | + | − | + | + | − |
| CD117 | − | − | − | − | − | − | − | − | − | − |
| Cytokeratin pan | − | − | − | − | − | − | − | − | − | − |
| Desmin | − | − | − | − | − | − | − | − | − | − |
| Epithelial membrane antigen | − | + | + | − | − | − | − | − | − | − |
| S-100 | − | − | + | − | − | − | − | − | − | − |
| Insulin receptor | + | + | − | + | + | + | + | + | − | − |
| IGF-1R | + | − | − | + | − | − | − | − | − | − |
| Ki-67 labeling index, % | >5 | 2 | 1 | 1 | 5 | 0 | 1 | 2 | 0 | 1 |
| Mitotic fields/10 HPFs | 10 | 1 | 0 | 1 | 3 | 0 | 1 | 2 | 0 | 0 |
| Cellularity | + | − | − | − | + | − | + | − | − | − |
| Pleomorphism | + | − | − | − | + | + | + | + | − | − |
| Necrosis | + | + | − | − | + | − | − | − | − | − |
| Risk scorea | 5 | 4 | 2 | 4 | 3 | 4 | 4 | 4 | 2 | 1 |
a
Risk model proposed by Demicco et al (7): Low risk, 0–2; moderate risk, 3–4; and high risk, 5–6.
CD, cluster of differentiation; IGF-1R, insulin-like growth factor 1 receptor; HPF, high-power field.